Overview Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis Status: Recruiting Trial end date: 2023-09-30 Target enrollment: Participant gender: Summary Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description Phase: Phase 3 Details Lead Sponsor: Galderma R&D